Literature DB >> 2686531

Molecular basis of cisplatin resistance in human carcinomas: model systems and patients.

K J Scanlon1, M Kashani-Sabet, H Miyachi, L C Sowers, J Rossi.   

Abstract

In this review, cisplatin resistance will be summarized. We will discuss characteristics of potential mechanisms of resistance in tissues from patients with ovarian, colon and breast carcinoma. Secondly, a new molecular biology assay will be discussed which detects changes in gene expression in cisplatin-resistant cells. Finally, based on the biochemical and molecular properties of cisplatin-resistant tumors, new strategies to exploit or circumvent cisplatin resistance in human tumors will be entertained.

Entities:  

Mesh：

Substances：

Year:  1989        PMID： 2686531

Source DB:  PubMed          Journal:  Anticancer Res        ISSN： 0250-7005            Impact factor:   2.480


  21 in total

1.  Activity and DNA binding of new organoamidoplatinum (II) complexes.

Authors:  T Talarico; D R Phillips; G B Deacon; S Rainone; L K Webster
Journal:  Invest New Drugs       Date:  1999       Impact factor: 3.850

2.  Cyclosporin A reverses chemoresistance in patients with gynecologic malignancies.

Authors:  A K Sood; J I Sorosky; R C Squatrito; J S Skilling; B Anderson; R E Buller
Journal:  Neoplasia       Date:  1999-06       Impact factor: 5.715

3.  Ribozyme-mediated cleavage of c-fos mRNA reduces gene expression of DNA synthesis enzymes and metallothionein.

Authors:  K J Scanlon; L Jiao; T Funato; W Wang; T Tone; J J Rossi; M Kashani-Sabet
Journal:  Proc Natl Acad Sci U S A       Date:  1991-12-01       Impact factor: 11.205

Review 4.  Cell-signaling targets for antitumour drug development.

Authors:  V G Brunton; P Workman
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

5.  Retained platinum uptake and indifference to p53 status make novel transplatinum agents active in platinum-resistant cells compared to cisplatin and oxaliplatin.

Authors:  Robert F Murphy; Edina Komlodi-Pasztor; Robert Robey; Frank M Balis; Nicholas P Farrell; Tito Fojo
Journal:  Cell Cycle       Date:  2012-03-01       Impact factor: 4.534

Review 6.  Drug resistance in brain tumors.

Authors:  L G Feun; N Savaraj; H J Landy
Journal:  J Neurooncol       Date:  1994       Impact factor: 4.130

7.  Antitumor drug cross-resistance in vivo in a cisplatin-resistant murine P388 leukemia.

Authors:  W R Waud; S D Harrison; K S Gilbert; W R Laster; D P Griswold
Journal:  Cancer Chemother Pharmacol       Date:  1991       Impact factor: 3.333

Review 8.  Signaling and drug sensitivity.

Authors:  R D Christen; S Isonishi; J A Jones; A P Jekunen; D K Hom; R Kröning; D P Gately; F B Thiebaut; G Los; S B Howell
Journal:  Cancer Metastasis Rev       Date:  1994-06       Impact factor: 9.264

9.  Molecular characterization of the in vivo alkylating agent resistant murine EMT-6 mammary carcinoma tumors.

Authors:  D Chatterjee; C J Liu; D Northey; B A Teicher
Journal:  Cancer Chemother Pharmacol       Date:  1995       Impact factor: 3.333

10.  Cytotoxicity and cellular accumulation of a new cis-diammineplatinum (II) complex containing procaine in murine L1210 cells sensitive and resistant to cis-diamminedichloroplatinum (II).

Authors:  M Viale; S Cafaggi; B Parodi; M Esposito
Journal:  Cancer Chemother Pharmacol       Date:  1995       Impact factor: 3.333
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.